Emerging Drug Developer: Argos Therapeutics

Emerging Drug Developer: Argos Therapeutics

Immunology is a hot topic in biotechnology these days, and Argos Therapeutics is gambling on its dendritic cell technology to get it past Phase II and into a new stage of development. With a drug platform aimed at cancer and infectious diseases, the Durham, NC-based developer is touting some early successes and some great expectations for the next two years. It's already managed to win over some of the leading names in global biotechnology as partners. And data due by mid-2009 will be crucial to its long-term success. Article

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.